Therapeutic Drug Monitoring-Guided Antifungal Therapy Under Tyrosine Kinase Inhibitor Treatment in an Advanced Osteosarcoma Patient with Invasive Pulmonary Aspergillosis
Ruiting Wen, Wentao Ni, Xiaotong Gu, Boyu Liu, Gali Bai, Xiaohong Zhang · 2025
Read Therapeutic Drug Monitoring-Guided Antifungal Therapy Under Tyrosine Kinase Inhibitor Treatment in an Advanced Osteosarcoma Patient with Invasive Pulmonary Aspergillosis by Ruiting Wen, Wentao Ni, Xiaotong Gu, Boyu Liu, Gali Bai, Xiaohong Zhang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751358.txt.
Description
Ruiting Wen and co-authors recount drug-level guided antifungal care for a teen with bone cancer and a lung mold infection in a 2025 case report. Invasive aspergillosis stalks patients after chemotherapy, and antifungal levels swing wildly between people. The boy, aged fourteen, also took targeted cancer drugs that can clash with antifungals.
Blood checks showed the first drug, voriconazole, sat far too low even after dose hikes, and the infection stalled. A switch to isavuconazole put levels in range and the lungs improved. Level checks also flagged one pairing that clashed and one that did not. Testing levels, the authors argue, should steer such care.
Catalog record
| CREATOR | Ruiting Wen, Wentao Ni, Xiaotong Gu, Boyu Liu, Gali Bai, Xiaohong Zhang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 14 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |